209 related articles for article (PubMed ID: 35158435)
1. COVID-19 outcomes in persons with multiple sclerosis treated with rituximab.
Iyer RB; S R; M JN; R J
Mult Scler Relat Disord; 2022 Jan; 57():103371. PubMed ID: 35158435
[TBL] [Abstract][Full Text] [Related]
2. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
[TBL] [Abstract][Full Text] [Related]
3. Vaccine hesitancy among people with multiple sclerosis.
Yap SM; Al Hinai M; Gaughan M; Callanan I; Kearney H; Tubridy N; McGuigan C
Mult Scler Relat Disord; 2021 Nov; 56():103236. PubMed ID: 34507240
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?
Claverie R; Perriguey M; Rico A; Boutiere C; Demortiere S; Durozard P; Hilezian F; Dubrou C; Vely F; Pelletier J; Audoin B; Maarouf A
Neurol Neuroimmunol Neuroinflamm; 2023 Sep; 10(5):. PubMed ID: 37604695
[TBL] [Abstract][Full Text] [Related]
5. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.
Mallucci G; Zito A; Baldanti F; Gastaldi M; Fabbro BD; Franciotta D; Bergamaschi R
Mult Scler Relat Disord; 2021 Apr; 49():102754. PubMed ID: 33609958
[TBL] [Abstract][Full Text] [Related]
6. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Sormani MP; De Rossi N; Schiavetti I; Carmisciano L; Cordioli C; Moiola L; Radaelli M; Immovilli P; Capobianco M; Trojano M; Zaratin P; Tedeschi G; Comi G; Battaglia MA; Patti F; Salvetti M;
Ann Neurol; 2021 Apr; 89(4):780-789. PubMed ID: 33480077
[TBL] [Abstract][Full Text] [Related]
7. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L
Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987
[TBL] [Abstract][Full Text] [Related]
8. Impact of the COVID-19 pandemic on the health care of >1,000 People living with multiple sclerosis: A cross-sectional study.
Vogel AC; Schmidt H; Loud S; McBurney R; Mateen FJ
Mult Scler Relat Disord; 2020 Nov; 46():102512. PubMed ID: 32977074
[TBL] [Abstract][Full Text] [Related]
9. Effect of the COVID-19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation.
Mariottini A; Lotti A; Innocenti C; Repice AM; Nozzoli C; Boncompagni R; Fainardi E; Saccardi R; Massacesi L
Eur J Neurol; 2023 Oct; 30(10):3362-3366. PubMed ID: 37483174
[TBL] [Abstract][Full Text] [Related]
10. Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab.
Melong Pianta Taleng CM; Lauper K; Gilbert B; Cunningham T; Guemara R; Brulhart L; Dan D; Courvoisier D; Finckh A
RMD Open; 2021 Dec; 7(3):. PubMed ID: 34862310
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: What we know by May 2021.
Naghavi S; Kavosh A; Adibi I; Shaygannejad V; Arabi S; Rahimi M; Mazaheri S; Ashtari F
Mult Scler Relat Disord; 2022 Jan; 57():103335. PubMed ID: 35158427
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab in Covid era.
Iovino A; Olivieri N; Aruta F; Giaquinto E; Ruggiero L; Spina E; Tozza S; Manganelli F; Iodice R
Mult Scler Relat Disord; 2021 Jun; 51():102908. PubMed ID: 33812222
[TBL] [Abstract][Full Text] [Related]
14. Depression, anxiety, and fear of COVID-19 in patients with multiple sclerosis in pandemic era: a cross-sectional study.
Alirezaei M; Eskandarieh S; Sahraian MA; Naser Moghadasi A
Neurol Sci; 2022 Jan; 43(1):59-66. PubMed ID: 34554334
[TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis, rituximab, and COVID-19.
Langer-Gould A; Smith JB; Li BH;
Ann Clin Transl Neurol; 2021 Apr; 8(4):938-943. PubMed ID: 33783140
[TBL] [Abstract][Full Text] [Related]
16. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
Front Immunol; 2021; 12():796482. PubMed ID: 35111162
[TBL] [Abstract][Full Text] [Related]
17. A year with the fear of COVID-19 in multiple sclerosis patients: Examination of depression, sleep quality and quality of life before and after the pandemic.
Yeni K; Tulek Z; Terzi M
Mult Scler Relat Disord; 2022 Jan; 57():103370. PubMed ID: 35158434
[TBL] [Abstract][Full Text] [Related]
18. Changes on the health care of people with multiple sclerosis from Latin America during the COVID-19 pandemic.
Chertcoff A; Bauer J; Silva BA; Aldecoa M; Eizaguirre MB; Rodriguez R; Chereque A; Rodríguez Heudebert ML; Milanesi V; Morales L; Castellón M; Mejía Pineda S; Ferrandina F; Henestroza P; Ruiz Peraza M; Vallecillo Rivas F; Cedeño Lopez L; Herrera L; Sosa M; Cruchet Muñoz V; Barahona AS; Ramírez Gudiño LM; Carballido S; Walton C; Peeters LM; Rijke N; Garcea O; Carrá A; Alonso R
Mult Scler Relat Disord; 2021 Sep; 54():103120. PubMed ID: 34243104
[TBL] [Abstract][Full Text] [Related]
19. Frequency and characteristics of falls in people living with and without multiple sclerosis during the COVID-19 pandemic: A cross-sectional online survey.
Zanotto T; Frechette ML; Koziel SR; Hsieh KL; Sosnoff JJ
Mult Scler Relat Disord; 2021 Sep; 54():103111. PubMed ID: 34303279
[TBL] [Abstract][Full Text] [Related]
20. Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations.
Pugliatti M; Berger T; Hartung HP; Oreja-Guevara C; Bar-Or A
Curr Opin Neurol; 2022 Jun; 35(3):319-327. PubMed ID: 35674075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
